CA-ESRI
6.10.2020 14:02:19 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced two major capabilities in Site Scan for ArcGIS that will enable governments and critical infrastructure organizations to meet hardware and software regulations in the US and Europe. Through an established partnership with Auterion, creator of the most widely used open-source drone autopilot operating system, security-conscious US organizations will be able to use Site Scan, Esri's unmanned aerial systems flight planning and processing solution, to plan and execute missions with the trusted and secure Freefly Astro drone, powered by Auterion. Additionally, for organizations in Europe with data sovereignty requirements, a new and fully independent instance of Site Scan for ArcGIS has been deployed to European servers, ensuring that organizational data resides within the region.
Site Scan for ArcGIS is used by organizations that require drone imagery for visual inspections, site monitoring, asset management, and situational awareness. It's an all-in-one, cloud-based drone mapping solution for managing fleets and collecting, processing, analyzing, and sharing data products. Industries using this solution include architecture, engineering, construction, natural resources, infrastructure, and government. Core capabilities in Site Scan—such as scalability, collaboration, time saving, and now enhanced security functionality—provide value to customers.
The US government has recently issued a growing number of advisory warnings and bans on the use of drones that pose security risks. These precautions have adversely impacted federal agencies and private firms that manage critical infrastructure, causing them to adopt incongruous drone data capturing and processing workflows that consist of multiple vendor solutions. Esri can now offer these agencies a single, end-to-end drone solution that integrates Freefly Astro, using US Department of Defense-approved Blue sUAS software architecture from Auterion, and is fully supported by Site Scan.
"Our expertise in providing an enterprise drone platform based on open-source software enabled us to meet the needs of the US government and governments worldwide," said Dave Sharpin, CEO, Auterion Government Solutions. "We are very excited to partner with Esri and provide [its] users with our groundbreaking technology."
By law within Europe, data from publicly funded or critical infrastructure projects cannot leave the European Union (EU). To enable a scalable drone workflow, Site Scan for ArcGIS has been deployed to a server cluster in Ireland. European customers that require their data not be transmitted outside the region can now leverage this server cluster to meet project requirements.
"The relationship we have established with Auterion is key in being able to offer high-quality, secure drone software to our US customers looking to take advantage of our advanced, secure, drone-based imagery collection and management platform," said Richard Cooke, Esri director of imagery and remote sensing. "Additionally, through the development of the EU deployment, an even wider range of customers located in Europe will be able to maintain their data and data processing locally."
The Freefly Astro and Site Scan integration will be available for customers by December 2020. The European deployment of Site Scan is available today. To learn more about the new integration of Site Scan with the Freefly Astro drone or about the EU deployment of Site Scan, contact the Esri sales team at esri.com/en-us/arcgis/products/site-scan-for-arcgis/overview#contactsales .
About Auterion
Auterion provides enterprise and government with an ecosystem of software-defined drones, payloads, and third-party applications within a single easy to use platform based on open-source standards.
With 50+ employees across offices in California and Switzerland, Auterion has raised $25M in venture-backed funding from investors such as Lakestar, Mosaic Ventures, Costanoa Ventures, and Tectonic Ventures. The company's global customer base includes GE Aviation, Quantum Systems, Freefly Systems, Avy, and the U.S. Government. Learn more at www.auterion.com .
Twitter: @auterion
LinkedIn: https://www.linkedin.com/company/auterion/
Facebook: https://www.facebook.com/auterion/
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005312/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom